Aulos Bioscience
United States
- Larkspur, California
- 01/08/2023
- Series A
- $20,000,000
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Industry Biotechnology Research
- Website https://aulosbio.com/
- LinkedIn https://www.linkedin.com/company/aulos-bioscience/
Helio AI | $1,000,000 | (Nov 27, 2025)
Procure Ai | $13,000,000 | (Nov 27, 2025)
Overstory | $43,000,000 | (Nov 27, 2025)
Global Work AI | $2,400,000 | (Nov 27, 2025)
SubImage (YC W25) | $4,200,000 | (Nov 27, 2025)
AUGMENTT | $18,000,000 | (Nov 27, 2025)
EcoG | $18,573,280 | (Nov 27, 2025)
Parallax Worlds | $4,900,000 | (Nov 27, 2025)
CoPlane | $14,000,000 | (Nov 27, 2025)
The Intelligent Search Company (TISC) | $2,100,000 | (Nov 27, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)